Advertisement

Topics

bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association

09:00 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes – - Oral presentation of interim...

Other Sources for this Article

bluebird bio, Inc.
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Media:
Stephanie Fagan, 201-572-9581
sfagan@bluebirdbio.com

NEXT ARTICLE

More From BioPortfolio on "bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...